pharmaceutical daily

Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symbol “GELS”NEW YORK, Oct. 28, 2024 (GLOBE…

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage…

Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) — Polyrizon Ltd. (the “Company” or “PLRZ”), a development stage biotech company specializing…

Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Oral presentation highlights findings that patients…

FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing…

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after…

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate…

First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability…

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints…

Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS…